CVT-4325 inhibits myocardial fatty acid uptake and improves left ventricular systolic function without increasing myocardial oxygen consumption in dogs with chronic heart failure.
Cardiovasc Drugs Ther
; 21(1): 9-15, 2007 Feb.
Article
em En
| MEDLINE
| ID: mdl-17119875
ABSTRACT
BACKGROUND:
Inhibition of myocardial fatty acid oxidation has been suggested as a therapeutic approach for improving cardiac function in chronic heart failure (HF). The novel piperazine derivative CVT-4325 was shown to inhibit fatty acid oxidation in cardiac mitochondria and in isolated perfused rat hearts. In the present study, we tested the hemodynamic and metabolic effects of acute intravenous CVT-4325 in dogs with HF. METHODS ANDRESULTS:
HF (LV ejection fractionCONCLUSIONS:
In dogs with HF, acute intravenous infusion of CVT-4325 reduces FFA uptake and improves LV systolic function without increasing MVO2. The improvement in LV systolic function in the absence of an increase in MVO2 and a lower FFA uptake is consistent with the concept that inhibition of myocardial fatty acid oxidation may be an effective treatment for HF.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Oxidiazóis
/
Consumo de Oxigênio
/
Função Ventricular Esquerda
/
Ácidos Graxos
/
Insuficiência Cardíaca
/
Miocárdio
Limite:
Animals
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article